Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 5/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8709942 | 1.00 | AHCY (0.58) | AHCYADORA2AADORA3ADORA1NT5E | |
| SCHEMBL12929183 | 1.00 | AHCY (0.58) | AHCYADORA2AADORA3ADORA1NT5E | |
| SCHEMBL12960582 | 1.00 | AHCY (0.58) | AHCYADORA2AADORA3ADORA1NT5E | |
| SCHEMBL3746390 | 1.00 | AHCY (0.58) | AHCYADORA2AADORA3ADORA1NT5E | |
| SCHEMBL3750374 | 1.00 | AHCY (0.58) | AHCYADORA2AADORA3ADORA1NT5E | |
| SCHEMBL8709225 | 1.00 | AHCY (0.58) | AHCYADORA2AADORA3ADORA1NT5E | |
| SCHEMBL3746380 | 1.00 | AHCY (0.58) | AHCYADORA2AADORA3ADORA1NT5E | |
| SCHEMBL8215983 | 0.89 | AHCY (0.55) | AHCYADORA2AADORA3ADORA1NT5E | |
| SCHEMBL8222030 | 0.89 | AHCY (0.55) | AHCYADORA2AADORA3ADORA1NT5E | |
| SCHEMBL8215986 | 0.89 | AHCY (0.55) | AHCYADORA2AADORA3ADORA1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939677-B2 | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation | ISIS PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324277-A1 | OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION | SNRPE, NSUN3, NSUN2 | AHCY 1651/4885ADORA2A 2653/4885ADORA3 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.